4-CN-CUMYL-BUTINACA

4-CN-CUMYL-BUTINACA is a synthetic cannabinoid that belongs to the indazole-3-carboxamide family of chemicals. It is an analog of CUMYL-PINACA, with the primary difference being the substitution of a cyano group at the para position of the benzyl ring. This modification is thought to affect the compound's affinity and selectivity for the CB1 receptor and CB2 receptor, which are the primary targets of action for cannabinoids in the human body. The effects and legal status of 4-CN-CUMYL-BUTINACA can vary significantly across different jurisdictions, reflecting the ongoing challenges in regulating novel psychoactive substances.

Chemistry

4-CN-CUMYL-BUTINACA is chemically classified as an indazole-3-carboxamide, with a specific interest in its cyano group substitution. This structural feature distinguishes it from its close relatives in the synthetic cannabinoid family, potentially altering its pharmacological profile. The compound's full chemical name is 1-(4-cyanobutyl)-N-(2-phenylpropan-2-yl)-1H-indazole-3-carboxamide.

Pharmacology

The pharmacological action of 4-CN-CUMYL-BUTINACA, like other synthetic cannabinoids, is primarily mediated through its interaction with the body's endocannabinoid system. It acts as an agonist at the CB1 and CB2 receptors, though the specific efficacy and potency at these receptors can vary compared to other cannabinoids. The presence of the cyano group may influence these interactions, though detailed pharmacological studies are limited.

Effects

The effects of 4-CN-CUMYL-BUTINACA on humans are not well-documented, largely due to its status as a novel psychoactive substance. However, based on the effects of closely related synthetic cannabinoids, it can be speculated that it may produce a range of psychoactive effects similar to THC, the active component in cannabis. These effects could include euphoria, altered perception, and potential adverse effects such as anxiety, paranoia, and physiological stress on the cardiovascular and nervous systems.

Legal Status

The legal status of 4-CN-CUMYL-BUTINACA varies by country and jurisdiction, reflecting the broader challenge of regulating synthetic cannabinoids. Many countries have moved to control such substances under analog acts or specific legislation targeting synthetic drugs, but the rapidly evolving nature of these compounds makes legal control a complex and ongoing issue.

Health Risks

As with other synthetic cannabinoids, the health risks associated with 4-CN-CUMYL-BUTINACA are potentially significant but not fully understood. The lack of clinical studies and reliable user reports means that the safety profile of this compound is largely unknown. Synthetic cannabinoids have been associated with severe adverse effects, including acute kidney injury, cardiovascular problems, and severe psychiatric effects.